LAVAL, Quebec, June 12, 2018 /CNW/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the introduction of Ocuvite® Blue Light eye vitamins, a nutritional supplement formulated with lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye. This formulation of eye nutrients includes high levels of lutein and helps protect eyes from the blue light that reaches the macula, which is responsible for our central vision.
"With the increasing number of hours Americans are spending on digital devices, there is a growing need for a product that helps our eyes filter the blue light that is emitted from these devices," said Joseph Gordon, president, Consumer Healthcare and Vision Care, Bausch + Lomb. "Ocuvite® Blue Light is specifically formulated to meet this need and help consumers maintain their eye health in our screen-centric world."
Most adults spend seven or more hours daily in front of digital devices, exposing themselves to blue light for an extended period of time. What many don't realize is that reducing their exposure to blue light can support their eye health. Ocuvite® Blue Light eye vitamins contain 25 milligrams of lutein and five milligrams of zeaxanthin isomers, the key eye nutrients that help absorb blue light before it reaches the macula.
"It is imperative to support the macular pigment layer, as it is a significant component of eye function that helps filter blue light," said Jeffry D. Gerson, O.D., FAAO, Grin Eye Care, Olathe, Kansas. "Since Ocuvite® Blue Light contains key ingredients naturally found in the macular pigment, I can now offer this new supplement to my patients to help them protect their eyes from blue light as part of their daily, digital lifestyles."
Ocuvite® Blue Light eye vitamins will be available for purchase in the vitamin and eye care aisles at major retailers in the third quarter of 2018 and have a suggested retail price of $16.99.
About Bausch + Lomb Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.
About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.
Forward-looking Statements This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Multi-Sponsor Surveys, Inc., The 2017 U.S. Study of Eye Health in the Digital Age